p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's lymphoma cell lines.
暂无分享,去创建一个
[1] M. Minden,et al. Alterations of p53 and c-myc in the clonal evolution of malignant lymphoma. , 1994, Blood.
[2] J. M. Lee,et al. p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[3] Yi-Song Wang,et al. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[4] X. H. Wang,et al. Constitutive production of the interleukins IL-5 and IL-6 by the lymphoma cell line OCI-Ly 17 derived from a patient with malignant lymphoma and hypereosinophilia. , 1992, Leukemia & lymphoma.
[5] M. Minden,et al. Growth of human lymphoma cells in SCID mice. , 1992, Leukemia & lymphoma.
[6] Gerard I. Evan,et al. Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.
[7] X. H. Wang,et al. A human lymphoma cell line with multiple immunoglobulin rearrangements. , 1992, The Journal of clinical investigation.
[8] J. Cleveland,et al. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.
[9] T. Crook,et al. p53 is frequently mutated in Burkitt's lymphoma cell lines. , 1991, The EMBO journal.
[10] K. Magnússon,et al. Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. , 1991, Oncogene.
[11] I. Weissman,et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.
[12] G. Gaidano,et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Minden,et al. Mutation of the p53 gene in human acute myelogenous leukemia. , 1991, Blood.
[14] T. Hunter. Cooperation between oncogenes , 1991, Cell.
[15] T. McDonnell,et al. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.
[16] D. Slamon,et al. Frequency and structure of p53 rearrangements in human osteosarcoma. , 1990, Cancer research.
[17] A. Strasser,et al. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.
[18] D. Lane,et al. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.
[19] T. Pawson,et al. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene , 1989, Molecular and cellular biology.
[20] X. H. Wang,et al. A possible autocrine role for interleukin-6 in two lymphoma cell lines. , 1989, Blood.
[21] R. Weinberg,et al. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. , 1989, Cancer research.
[22] H. Koeffler,et al. Rearrangement of the p53 gene in human osteogenic sarcomas. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[23] M. Minden,et al. The presence of clonogenic cells in high-grade malignant lymphoma: a prognostic factor. , 1987, Blood.
[24] D. Pim,et al. Primary structure polymorphism at amino acid residue 72 of human p53 , 1987, Molecular and cellular biology.
[25] L. Banks,et al. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. , 1986, European journal of biochemistry.
[26] J. Sklar,et al. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[27] E. Gelmann,et al. Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Pim,et al. Monoclonal antibodies specific for simian virus 40 tumor antigens , 1981, Journal of virology.
[29] W. Rutter,et al. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.
[30] E. Lehmann,et al. Nonparametrics: Statistical Methods Based on Ranks , 1976 .
[31] N. Berinstein,et al. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. , 1994, Blood.
[32] J. Lotem,et al. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[33] A. Patel,et al. myc function and regulation. , 1992, Annual review of biochemistry.
[34] S. Cory,et al. Oncogene co-operation in leukaemogenesis. , 1992, Cancer surveys.
[35] H. Toutenburg,et al. Lehmann, E. L., Nonparametrics: Statistical Methods Based on Ranks, San Francisco. Holden‐Day, Inc., 1975. 480 S., $ 22.95 . , 1977 .